Cannabinoid/psychedelic leadership Purisys is a global leader in custom synthesis of cannabinoids and psychedelics with multiple DEA licenses and GMP capabilities, presenting a strong USP for pharma/biotech partners pursuing regulated substance APIs, reference standards, and end-to-end CDMO services.

Global reference standards In-stock reference standards numbering over 250 with broad geographic reach (30+ countries on 6 continents) create cross-sell opportunities to clients needing reliable analytical materials alongside custom API development.

End-to-end CDMO Full-service development to commercial API manufacturing in FDA-inspected GMP suites, including HPAPI, labile molecules, and complex/controlled substances, enabling Purisys to win projects requiring seamless scale-up and regulatory readiness.

Strategic backing Now part of the Siegfried group with expanding manufacturing footprint and leadership depth, Purisys can leverage larger corporate resources, financing and global network to pursue larger, multi-site programs.

Regulatory-ready footprint Multiple DMFs and established regulatory filings (e.g., dronabinol, CBD, nabilone) indicate strong regulatory maturity, offering a compelling value proposition to clients seeking compliant development timelines and robust documentation.